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Clinical trialSigniﬁcant work has been done towards identifying the health-beneﬁcial effects of the grape antioxidant resver-
atrol in a variety of bioassay- and disease- models, with much research being focused on its possible application
to cancer management. Despite the large number of preclinical studies dealing with different aspects of the
biological effects of resveratrol, its translation to clinics is far from reality due to a variety of challenges. In this
review, we discuss the issues and questions associated with resveratrol becoming an effective in vivo anticancer
drug, from basic metabolic issues to the problems faced by incomplete understanding of the mechanism(s) of
action in the body. We also explore efforts taken by researchers, both public and private, to contend with some
of these issues. By examining the publisheddata andprevious clinical trials,wehave attempted to identify the prob-
lems and issues that hinder the clinical translation of resveratrol for cancer management. This article is part of a
Special Issue entitled: Resveratrol: Challenges in translating pre-clinical ﬁndings to improved patient outcomes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Worldwide, cancer is one of themost frequently diagnosed diseases
and is a major cause of loss of human life. Because of the intense treat-
ment regimens and/or surgeries necessary to treat this malignancy, a
diagnosis of cancer puts a major economic burden on the suffering
family aswell as on communities and society. Alarmingly, approximate-
ly 12.7 million cancer diagnoses and 7.6 million cancer deaths were ex-
pected to have occurred in 2008 throughout theworld [1]. In the United
States alone, 1,665,540 new cases of cancer and 585,720 cancer related
deaths are estimated for the year 2014 [2]. Interestingly, there are areas
throughout the world where certain cancers are less prominent, which
could be attributed to prevailing local dietary habits and/or use of natu-
ral agents as medicines/remedies [3,4]. In the recent past, increasing
research efforts have attempted to make use of these observations and
advocate the use of natural agents, alone or in combination with tradi-
tional therapeutics for cancer management. The grape antioxidant res-
veratrol (chemically: 3,5,4′-trihydroxystilbene) is one such agent that
has been studied at large for its health-promoting effects, as evidenced
from the over 6800publications available at present on PubMed. Almost
one third of these articles have explored the link between resveratrol
and cancer, indicating that this natural compound may hold tremen-
dous promise in the ﬁeld of cancer management.atrol: Challenges in translating
, University of Wisconsin, 1300
el.: +1 608 263 5359; fax: +1Resveratrol is a naturally occurring phytoalexin, a substance synthe-
sized de novo by plants, to counteract pathogen infections. In preclinical
studies, resveratrol has been shown to enhance vascular health by
reducing hypertension and counteracting against heart failure and ische-
mic heart disease in experimental animal models (reviewed in [5]). Fur-
ther, there is ample evidence that resveratrol protects against high fat
diet-induced obesity, improves insulin sensitivity, lowers serum glucose
levels in several animal models, and improves diabetic kidney disease
in rodents (reviewed in [5]). Similarly, resveratrol has been shown to
have neuroprotective effects in experimental models of cerebral stroke
[6]. Studies have also suggested that resveratrol can partially mimic the
effects of a calorie restricted diet, which is known to slow the aging pro-
cess and extend lifespan in diverse species ([7] and reviewed in [8,9]).
Although the exact mechanisms of the health-promoting effects of res-
veratrol are still being explored, the promising pharmacologic properties
of resveratrol have allowed for its entry into the unregulated nutraceuti-
cal sector in the form of over-the-counter nutritional supplement. It is
still unclearwhether this is a good thing, as the clinical beneﬁts of resver-
atrol are yet to be realized. Although this interesting compound seems to
have potential against a variety of diseases/conditions, one of its most
evident health beneﬁts is its ability to elicit chemopreventive as well as
therapeutic effects against several cancers [10]. The cancer chemopreven-
tive properties of resveratrol were ﬁrst discovered in 1997 by Jung and
colleagues, when they demonstrated the anti-initiation, anti-promotion,
and anti-progression activities of resveratrol in different models [10].
Building on this research, other investigators have shown that resveratrol
inhibits tumor growth in vivo against several cancer types,which are dose
and duration dependent (reviewed in [11]).
Although in vitro and animal experimental data are extremely
promising for resveratrol's anti-proliferative effects, there is limited
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this translation is the limited bioavailability of resveratrol as it is
metabolically eliminated from the body extremely fast, so much so
that it is difﬁcult to maintain a therapeutically relevant level in the
bloodstream [12,13]. Recently, we have advocated the use of other
natural agents in combination with resveratrol to improve the over-
all therapeutic effectiveness, especially for cancer management
(reviewed in [14]). One example of this is our recent hypothesis
that resveratrol, when given in combination with zinc (Zn), may
modulate in vivo Zn-homeostasis to enhance the cellular transport
of Zn into the prostatic tissue viamodulating zinc transporter proteins,
thereby enhancing the therapeutic efﬁcacy of Zn against prostatemalig-
nancy [15]. Similarly, there are considerable ongoing efforts to try to
exploit resveratrol's potential against cancer via combining it with
other compounds/drugs, in order to tackle some of the limitations and
to increase the overall therapeutic efﬁcacy.
On the whole, resveratrol has been found to be effective against a
number of human cancers in preclinical studies, suggesting that it
could be a useful chemotherapeutic agent. A positive property of resver-
atrol is the fact that it is well tolerated in most patients and appears to
have minimal side effects even at very high doses (reviewed in [16]).
However, the immense potential that appears to be present in preclini-
cal testing has yet to be realized in human trials. This has been explored
in many reviews, including two recent ones that discuss the overall
challenges of using resveratrol in humans for multiple conditions [17,
18]. In this review, we are focusing on presenting a critical discussion,
including relevant clinical studies, to understand the challenges associ-
ated with bringing resveratrol into the clinical realm as an anticancer
drug. As outlined in Fig. 1, there are speciﬁc areas of resveratrol research
that need to be extensively explored that may pave theway for efﬁcient
translation of resveratrol from the bench to the bedside.
2. Bioavailability, absorption and metabolism of resveratrol
The limited bioavailability of resveratrol is perceived as a major
hindrance in the potential clinical use of resveratrol for cancer manage-
ment. In vivo, resveratrol is absorbed through the gastrointestinal tract
and is rapidly metabolized to its stable glucuronides, sulfates, and
hydroxylates. In healthy humans, resveratrol has been demonstrated
to be metabolized to its 3- and 4′-O-sulfate, and 3-O-glucuronide
conjugates less than 2 h after ingestion [19]. Intestinal bacteria also
play a role in the metabolism of resveratrol that contributes to a varia-
tion of the fractional ratio of metabolites among individuals. Bode and
colleagues have shown that resveratrol can be metabolized by humanFig. 1. Speciﬁc research areas to be prioritized for resveratrol research. This ﬁgure outlines some
in the lab to being an ideal chemopreventive and chemotherapy agent.gut microbiota, resulting in dihydroresveratrol, 3,4′-dihydroxy-trans-
stilbene and 3,4′-dihydroxybibenzyl [20]. Pharmacokinetic proﬁles of
resveratrol in healthy volunteers displayed rapid and extensive metab-
olism to resveratrol-4′-O-glucuronide, resveratrol-3′-O-glucuronide,
and resveratrol-3-O-sulfate following single or multiple oral doses of
resveratrol between 0.5 and 5.0 g each [19,21]. This does not leave
much opportunity for resveratrol to impart its anticancer action, even
with a large dose being delivered. Thus, there are ongoing efforts to
somehow slow themetabolism of resveratrol to allow for increased tis-
sue exposure in the body. In this direction, we recently proposed some
possible scenarios to enhance resveratrol's bioavailability, such as
mechanism-based combinations with natural agents that can inhibit
the in vivometabolism of resveratrol, nanoparticle-mediated delivery,
use of naturally occurring or synthetic analogues of resveratrol, and
use of conjugated metabolites of resveratrol (reviewed in [22]).
Themost direct way to boost the efﬁcacy of resveratrol is to increase
the amount of free resveratrol available at the target organ site. For this
purpose, using other moieties, preferably naturally occurring agents, to
delay the rapid metabolic elimination of resveratrol, may be useful. In
this regard, in a study fromour laboratorywe have shown that piperine,
an alkaloid derived from black pepper (Piper spp.) improves in vivo bio-
availability of resveratrol in mice by inhibiting its glucuronidation [23].
At present, piperine is being considered as a bioavailability enhancer of
resveratrol by several private industries. Some other studies further
provide reasons to test this combination in greater detail. Huang et al.
recently found a synergistic effect of resveratrol and piperine combina-
tion on depressive-like behaviors in mice, which may be partly due to
the potentiated stimulation of the monoaminergic system in the brain
[24]. However, this study did not examine whether or not the addition
of piperine affects the bioavailability of resveratrol, as theywere focused
on determining the mechanism of action. In another recent study,
Wightman and colleagues demonstrated that piperine can increase the
bioefﬁcacy of resveratrol when co-supplemented in healthy human sub-
jects with regard to cerebral blood ﬂow effects [25]. In this study, co-
supplementation of piperine and resveratrol was found to signiﬁcantly
augment cerebral blood ﬂow during task performance without affecting
cognitive function, mood or blood pressure. Interestingly, no changes
were noticed in resveratrol's bioavailability. This may be due to themet-
abolic differences inmice vs. humans, whichmay impose a big challenge
in the translation of animal data to human studies.
Curcumin, a polyphenolic constituent of the popular South Asian
spice turmeric, has also been shown to inhibit glucuronidation in
mice by Basu and colleagues [26]. Recently, Malhotra and colleagues
demonstrated a synergistic chemopreventive response of curcuminof the key areas that need to be focused on in order to push resveratrol frombeing a success
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sis [27]. However, this study didn't assess the effect on the bioavail-
ability of these agents. Similarly, the polyphenol quercetin has been
shown to inhibit in vivo sulfation of resveratrol [28]. Thus, a combi-
nation of resveratrol with quercetin may enhance the bioavailability
of resveratrol by inhibiting both its glucuronidation and its sulfation.
Interestingly, resveratrol has a natural association with quercetin as
both polyphenols co-exist in red grapes, red wine and several other
plants. This combination was evaluated by McAnulty and colleagues
who examined it as a countermeasure against oxidative stress and
inﬂammation in response to exercise in athletes [29]. They found
that a combination of resveratrol and quercetin signiﬁcantly reduced
exercise-induced lipid peroxidationwithout associated changes in plas-
ma antioxidant status and inﬂammation. However, in this study the re-
searchers did not directly measure the serum levels of resveratrol or its
metabolites. Therefore, it is difﬁcult to determine whether quercetin
inhibited the metabolism of resveratrol, or if there was an additive or
combinatorial effect between the two agents. These studies open up
future avenues where novel means could be identiﬁed to slow down
the metabolism of resveratrol. Rapid clinical trials could be undertaken
to assess the usefulness of such combinations and/or to eliminate the
unsuccessful ones.
3. Resveratrol's metabolites, derivatives, and reformulations
Because of the rapid metabolism of resveratrol into its metabolites,
its undisputed effectiveness as found in several in vitro and in vivo stud-
ies leads some researchers to believe that resveratrol metabolites may
have their own biological activity that is different from the activity of
free resveratrol. Interestingly, there is some indication that resveratrol
metabolites, especially resveratrol 3-sulfate could also afford che-
mopreventive effects [30]. This leads to an interesting research ques-
tion as to whether resveratrol or its metabolites are the active
molecule(s) in vivo. As illustrated in Fig. 2, it is possible that the ob-
served anti-proliferative effects of resveratrol may be due to a com-
bination of actions by resveratrol and its metabolites. In fact, recent
studies have demonstrated that resveratrol sulfates can provide an
intracellular pool fromwhich resveratrol can be freed throughmetabolic
regeneration/deconjugation, ultimately inﬂicting its anti-proliferative ef-
fects in cancer cells [31,32]. Patel and colleagues performed the pharma-
cokinetic analysis of amixture of resveratrol-3-O-sulfate and resveratrol-
4′-O-sulfate inmice,which revealed that hydrolysis of sulfate-conjugates
generates free resveratrol. Further, monosulfate metabolites were also
noticed to be converted to resveratrol in human colorectal cancer cells.
This study suggests that resveratrol may be delivered to target tissues
in a sulfate-conjugated stable form, from which the parent resveratrol
could be steadily regenerated to elicit beneﬁcial effects in vivo [31].Fig. 2. An equilibrium between resveratrol and its metabolites. In the body, resveratrol and its m
elicit anti-cancer responses and signaling.This provides an excellent opportunity that needs to be veriﬁed in addi-
tional studies, including in human trials. A cartoon depicting the process
of regeneration of resveratrol from its conjugates, resulting in its anti-
tumor effects is outlined in Fig. 3.
In the recent past, a number of laboratories have attempted to syn-
thesize novel resveratrol derivatives or formulations [33]. However,
limited efforts have been put forward to determine if these derivatives
are superior to resveratrol in relevant disease models. Because of the
poor bioavailability of resveratrol, it may be useful, especially for cancer
chemoprevention, if resveratrol content could be increased in diets. To
this end, recently multiple methods have been studied in an attempt
to increase the content of resveratrol endogenously in wine products
and grape juices using UV irradiation and/or ozonisation of grapes
(reviewed in [34]). These types of studies are important as high-
resveratrol containing diets would allow an increase in the daily resver-
atrol intake of individuals.
In an interesting study, Larrosa and colleagues have reformulated
resveratrol to devise a set of resveratrol-prodrug forms (in this case,
acyl-glucosyl derivatives) that resist absorption in the upper gastroin-
testinal tract and are then able to be steadily de-conjugated during
gastrointestinal transit to supply an effective dose of free resveratrol
to the colonic mucosa [35]. The prodrug strategy takes advantage of
using a derivative of the original drug that can last longer in the body,
either by rendering it temporarily inactive or less active, thereby
allowing it to become active through normal metabolic processes at a
later time. This can be taken further by adding other chemical groups
that break down in sequential steps, resulting in a pro-prodrug. Larrosa
and colleagues found that mice fed with a very low dose of pro-
prodrugs of resveratrol did not develop colitis symptoms and improved
the disease activity index 6-fold compared to regular resveratrol. They
also noticed that these pro-prodrugs were able to i) prevent the rapid
metabolism of resveratrol, thereby delivering higher quantities of
resveratrol to the colon, and ii) reduce mucosal barrier imbalance
and prevent diarrhea [35]. This suggests that using these resveratrol
pro-prodrugs would be helpful in themanagement of colon cancer in
the human population. Another approach to reformulating resvera-
trol is to attempt to change its structure or place it into a carrier
that would allow it to reach the desired site in a targeted fashion
before it is metabolized, thus allowing it to exert beneﬁcial effects
in localized areas. A recent study shows that the pharmacokinetics-
and formulation-related limitations of resveratrol, as well as of other
polyphenols, can be controlled by entrapping the molecule of interest
inside unique structures such as dendrimers, which can be easily
tailored for speciﬁc purposes [36,37]. These and other changes can be
explored in order to attempt to change resveratrol's chemical proper-
ties, or targeting abilities, which leaves this area of research wide
open and interesting.etabolites naturally strive to reach a balance, at which point the activemoieties are able to
Fig. 3. A schematic representation of the process of regeneration of resveratrol from its conjugates, leading to their anti-proliferative effects. Research has shown that the body can absorb
both resveratrol and its metabolites through various parts of the digestive tract. Interestingly, once these moieties reach the tissue level, some of the metabolites can be regenerated into
the original resveratrol molecule. This allows both resveratrol and its metabolites better access to the tissues in order to elicit an anti-cancer response.
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One of the most encouraging aspects of resveratrol for its possible
development as an anti-cancer drug is that it does not appear to have
debilitating or toxic side effects, especially when compared with tradi-
tional chemotherapy treatments. A wide range of resveratrol doses have
been used in animal studies. For example, resveratrol has been shown
to be well-tolerated in rats, without toxic effects up to 750 mg/kg
bodyweight per day [38]. However, it is important for us to focus our
efforts on ﬁnding the most appropriate dose and route of resveratrol
administration, based on speciﬁc circumstances. For example, for
cancers of the gastrointestinal tract, even lower doses may be useful
because of increased exposure of the target organ with resveratrol. For
other cancers that are less accessible, local delivery of resveratrol
instead of systemic may be the ideal route of administration. Ginkel
and colleagues noticed rapid tumor regression in a mouse xenograft
model of human neuroblastoma when resveratrol was administered
via peritumor injection. They also noticed signiﬁcant evidence of cell
death in tumor tissue with relatively no effect in adjacent normal tis-
sues [39]. The discrimination in the cellular uptake of resveratrol be-
tween normal and tumor cells could be due to differences in the
molecular status and available cellular targets in cancer cells, which
may mean that resveratrol could have tumor-speciﬁc abilities. This is
likely the reason that resveratrol has such low numbers of toxic side
effects, and will allow researchers to be able to ﬁne-tune doses
to each disease's speciﬁc demands. Mukherjee and collogues have
reviewed the dose-dependent effects of resveratrol in relation to health
beneﬁts (both in animal and human studies), and have suggested that
lower doses of resveratrol could be very useful in maintaining human
health, while higher doses may be desirable to kill tumor cells via pro-
apoptotic effects [40].
Several human pharmacokinetic and pharmacodynamic studies of
resveratrol have been performed (reviewed in [41]). Based on these
studies, resveratrol does not appear to have side effects up to a dose of
1.0 g of resveratrol in the short term. However, when patients were
given 2.5 g or more per day, the observed side effects included diarrhea,
vomiting, nausea and evidence of liver dysfunction in patients with
non-alcoholic fatty liver disease [42]. Interestingly, no severe side effects
were reported in long-term clinical trials involving administration up to
16 mg resveratrol (for up to one year) in combination with other
grape polyphenols in poly-medicated subjects undergoing primary
and secondary prevention of cardiovascular disease [43]. In fact,
resveratrol has been found to be safe and reasonably well-tolerated at
up to 5 g/day, either as a single dose or as part of a multiple-day dosing
regimen (reviewed in [16]). However, when using this drug in cancer or
diseased patients, it is imperative to realize that these studieswere donein healthy populations. For example, in one study, a proprietary formu-
lation of resveratrol, SRT501 (developed by Sirtris, a GSK Company),
given at a dose of 5 g per day (alone or in combination with the
chemotherapy drug bortezomib) demonstrated renal toxicity in multi-
ple myeloma patients [44]. However, no renal toxicity was observed
when the same formulation was administered to healthy controls,
type 2 diabetics, or patients with mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like episodes (MELAS) syndrome [44]. This
suggests that choosing the right dose of resveratrol to target a speciﬁc
disease may be tricky. An optimal or even relevant dose for resveratrol
has still to be ascertained for different indications in carefully done
human clinical studies.
5. Resveratrol's mechanism of action as an anticancer agent
Despite the promising efﬁcacy of resveratrol to inhibit and suppress
tumor growth in several in vitro cancer studies, the exact mechanism of
resveratrol's anti-proliferative effects are still being investigated. In this
direction, there are many complicating factors because the malignant
cells display deregulations of multiple signaling pathways, leading to
uncontrolled cell proliferation, inhibition of programed cell death,
enhanced angiogenesis and enhanced uncontrolled migration of cells.
The available literature suggests that in cancer, resveratrol acts through
multiple mechanisms, including proapoptotic, antiproliferative, anti-
inﬂammatory, and anti-angiogenesis mechanisms. For example, it has
been suggested that one of resveratrol's direct targets is TANK-binding
kinase 1 (TBK1), an integral component in many chronic inﬂammatory
diseases, whichmay lead to cancer [45]. Similarly, Nwachukwu and col-
leagues have suggested that the anti-inﬂammatory effects of resveratrol
may be regulated via estrogen receptor-α [46]. In addition, it has also
been suggested that in stem-like cells derived from breast cancer
lines, resveratrol's apoptosis activity comes through its ability to
down-regulate fatty acid synthase (FAS) and enhance DAPK2 and
BNIP3, which are both pro-apoptosis genes [47]. Although it is difﬁcult
to ascertain the cause and effect mechanism in in vivo settings, resvera-
trol has been shown to affect a number of molecular targets, possibly
based on cancer type, resveratrol formulations, stage of disease, and
dose and duration of resveratrol. It is being increasingly appreciated
that the combinatorial approaches of resveratrol with other natural
agents are likely to be especially useful in advanced stages of cancers
because of deregulation of multiple pathways affecting cancer cell
growth and oncogenic signaling (reviewed in [14]). Interestingly, natu-
rally occurring agents tend to target multiple pathways, which makes
them ideal for this use.
Our understanding of mechanisms of action is further complicated
by the ﬁnding that orally delivered resveratrol is also metabolized by
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body that the hydroxylated forms of resveratrol are produced, which
have been shown to be effective cytotoxic molecules of their own. As
discussed previously, this is also true of many of the other resveratrol
metabolites. This complicates the issue and makes it difﬁcult for re-
searchers to determine if and which effects are due to resveratrol and
which ones are due to its metabolites. This should not be an issue in
the overall objective of using resveratrol for cancer management, as
the overarching goal is to eliminate cancer cells. It is possible that
in vivo, an interplay between resveratrol and its metabolites acting on
either the same or different molecular targets may be accountable for
the overall beneﬁcial health effects. For example, a molecular modeling
study by Calamini and colleagues [48] has shown that some of the
known targets of resveratrol such as COX-1 (cyclo-oxygenase-1) and
COX-2, both are potently inhibited by resveratrol as well as resveratrol
4′-O-sulfate (a resveratrol metabolite) [49]. However, when determin-
ing which doses, combinations, and routes of administrations are best
for each cancer type, the details of each mechanism may become very
important. The issue is further complicated by the fact that it is not
clear if resveratrol's anti-proliferative effects are due to direct effects
of resveratrol on tumor cells or indirect effects on angiogenesis or as a
result of binding to an extracellular target. In-depth research is needed
to understand these intricacies of mechanisms of resveratrol's action.
6. Resveratrol in the pharmaceutical industry and supplement
market
The health promoting potential of resveratrol has attracted many
pharmaceutical companies to try to develop this agent for the supple-
ment market. For example, as evident from an internet search, the com-
panyBiotivia Longevity Bioceuticals has developed amicro-encapsulated
formulation, Transmax TR,whichwas designed to protect the resveratrol
from stomach acid in order to provide a steady release into the blood
stream. Similarly, RevGenetics Micronized Trans-Resveratrol powder
claims to be absorbed up to 220% better as compared to regular resvera-
trol supplements. MicroActive® Resveratrol SR is another proprietary
formulation of resveratrol developed by BioActives. This compound
claims to be capable of providing a sustained release over 12 h to increase
intestinal residence time. Further, in a pilot study posted on the website
of the company, healthy subjects administered MicroActive® Resvera-
trol SR capsules after breakfast were found to have resveratrol in their
blood for a longer time than a regular resveratrol formulation. However,
limited information is available regarding these propriety formulations
and the testing done on them in the mainstream scientiﬁc literature. In
one of the few papers available, a pilot study done by Howells andTable 1
Published human studies assessing the effect of resveratrol against cancer.
Resveratrol formulation and dosages Cancer type Sample si
phase
Resveratrol (20 or 80 mg/day) or Grape Powder
(80 or 120 g/day) for 14 days
Colon n = 8
Phase 1
Resveratrol (0.5 or 1.0 g) for 8 days Colon n = 20
Micronized resveratrol, (SRT501, 5.0 g) for 14 days Colorectal with
hepatic metastases
n = 9
Phase 1
Micronized resveratrol, (SRT501, 5.0 g) for 20
consecutive days in a 21 day cycle for a max
of 12 cycles
Multiple myeloma n = 24
Phase 2
Polygonum cuspidatum caplets (5 or 50 mg
trans-resveratrol) twice daily for 12 weeks
Women at increased
breast cancer risk
n = 39
Resveratrol (0.5, 1.0, 2.5, or 5.0 g) for 29 days Healthy participants n = 40
Phase 1colleagues has assessed the safety, pharmacokinetics, and pharmacody-
namics of SRT501, a micronized form of resveratrol designed by Sirtris,
a GSK Company. They found that SRT501was tolerable, detectable in he-
patic tissue and with higher resveratrol levels in plasma as compared to
previously published data. The time required to reach the highest level
of resveratrol was also extended in the SRT501 patients. This trial used a
dose of 5 g daily for 14 days, and included patients with colorectal can-
cer and hepatic metastases who had been predetermined to undergo
hepatectomy [50]. Similar efforts are needed from industries to come
forward to join hands with researchers in undertaking well-designed
clinical trials.
7. Lessons learned from clinical studies
As available on ClinicalTrials.gov, the database of public and private-
ly supported human clinical studies, there are a total of 81 resveratrol
studies. Many of these trials have been done to evaluate the safety,
tolerability, pharmacokinetics and bioavailability of resveratrol. Only a
small number of listed studies are focused on evaluating the efﬁcacy
of resveratrol in certain cancers. A summary of these studies is provided
in Tables 1 and 2, which outline the completed and ongoing trials,
respectively. These trials use various forms of resveratrol, including
trans-resveratrol, extract of Polygonum cuspidatum (Japanese knot-
weed), SRT501 (micronized resveratrol), resveratrol rich seedless red
grapes/grape juices (Muscadine grapes), and micro-encapsulated
resveratrol. These trials are focused on several cancer types, including
multiple myeloma, breast cancer, follicular lymphoma and neuroendo-
crine tumors, but the majority are focused on assessing the effects of
resveratrol on the development of colorectal cancers. In fact, resveratrol
has proven to bemildly successful in colon cancer clinical trials, possibly
because of a potentially direct contact and prolonged exposure of res-
veratrol with colonic tissues. In addition, the intestinal epithelium
seems well adapted for absorption of nutrients and active molecules
from food/food components.
7.1. Completed clinical studies
Nguyen and colleagues were the ﬁrst to report their clinical trial on
resveratrol in cancer [51]. They evaluated the effects of either a
low dose of plant-derived resveratrol formulation or a resveratrol-
containing freeze-dried grape powder (GP) on Wnt signaling in colon
cancer patients, and found signiﬁcant inhibition in Wnt target gene
expression in normal colonic mucosa, with no change in the cancer tis-
sue [51]. The cancer tissue and normal colonic mucosa were obtained
from the same patient at the time of surgical resection and processedze & Outcome of the study Ref
Inhibition of Wnt signaling in normal colonic mucosa as indicated by
a reduction in the expression of a panel of Wnt target genes.
[51]
Resveratrol and its metabolites were quantiﬁed in colon tissues.
Higher levels were noticed in the right side of the colon. Reduction of
tumor cell proliferation by 5% (Ki-67 immunostaining, P = 0.05).
[52]
Found to be well tolerated, with higher mean plasma resveratrol level
(3.6-fold), detectable resveratrol in hepatic tissue and increased the
cleavage of caspase-3 by 39% in malignant hepatic tissue.
[44]
This clinical trial was designed to assess giving SRT501 with or
without bortezomib to Multiple Myeloma patients. However, due to
severe adverse events and minimal efﬁcacy in patients, the study
was terminated early.
[42]
RASSF-1αmethylation decreased with increasing levels of serum
resveratrol. This change was directly related to the change in
prostaglandin (PG)E2.
[53]
Generated micromolar concentrations of resveratrol and much
higher levels of glucuronide and sulfate conjugates in plasma.
Decreased circulating levels of cancer biomarkers IGF-I and IGFBP-3.
[42]
Table 2
Ongoing clinical trials on resveratrol and cancer (listed in ClinicalTrials.gov).
Resveratrol formulation and dosages Cancer NCT number/
patients/phase
Title of the study Objective of the study
Resveratrol (to be determined) for up to
8 days
Colorectal
adeno-carcinoma
NCT00433576
n = 20
Phase 1
Resveratrol in Treating Patients With
Colorectal Cancer That Can Be Removed
By Surgery
Determine relationship between oral dose
of resveratrol and the colon mucosal levels,
and the correlative level of COX-2 and M1G
in colorectal cancer tissues and WBCs.
Resveratrol (2.5 g) twice daily for a total
of three cycles in 28 day cycles
Neuro-endocrine
tumor
NCT01476592
n = 7
A Biological Study of Resveratrol's Effects
on Notch-1 Signaling in Subjects With
Low Grade Gastrointestinal Tumors
To determine if Notch1 and other
neuroendocrine marker levels are affected
in patients by resveratrol and that 5 g/day
will be well tolerated with minimal dose
limiting toxicities.
Seedless red grapes (1/3, 2/3 or 1 lb/day)
for up to 2 years
Colon cancer NCT00578396
n = 30
Phase 1
Phase I Biomarker Study of Dietary
Grape-Derived Low Dose Resveratrol
for Colon Cancer Prevention
Deﬁne the minimum dietary achievable
resveratrol levels via fresh red grapes, and
to see if it affects mucosa cell proliferation
(Ki-67 analysis of pre- and post-resveratrol
biopsy specimens).
100% Grape juice (495 or 660 ml) every
2nd day for 16 weeks
Follicular lymphoma NCT00455416
n = 45
Phase 2
Dietary Intervention in Follicular
Lymphoma
To assess the ability of dietary factors to
induce apoptosis, inhibit cell proliferation
and modulate tumor cell inﬁltrate in
Follicular Lymphoma of stage III/IV.
1183C.K. Singh et al. / Biochimica et Biophysica Acta 1852 (2015) 1178–1185identically. However, patients treated with resveratrol or GP had no
change in the composite Wnt target gene expression in colon cancer.
In fact, several of the genes, includingmyc and cyclinD1,were ampliﬁed
in the cancer tissue after exposure to grape powder, but no change was
seen following exposure to resveratrol. However, this was a pilot study
with a small number of participants for a short duration, designed to see
biomarker endpoints assessing the expression of various components
and target genes of the Wnt pathway. One issue with this trial was
that the researchers were initially told that the plant-derived resver-
atrol capsules contained 20 mg of trans-resveratrol; however, the
HPLC analysis revealed only 3.886 mg per capsule [51]. In addition,
quercetin was also found to be present in the capsules. This trial
stresses the importance of picking the right formulation/dose of
resveratrol in future trials. Another issue that will be important for
future trials is the issue of quality control to ensure there are no unex-
pected interfering effects.
Patel and colleagues reported the detection of resveratrol and its me-
tabolites in human tissues [52]. They identiﬁed and quantitated the level
of resveratrol as well as its metabolites resveratrol-3-O-glucuronide,
resveratrol-4′-O-glucuronide, resveratrol-3-O-sulfate, resveratrol-4′-O-
sulfate, resveratrol sulfate glucuronide, and resveratrol disulfate by
HPLC/UV in colorectal resection tissue. In this study, 0.5 and 1.0 g doses
of resveratrol were shown to reduce tumor cell proliferation by 5%
collectively in all the colon cancer patients [52]. This is despite the high
variability in resveratrol concentrations measured in the colorectal
tissues of patients. The authors suggested that the doses administered
are sufﬁcient to deliver enough resveratrol to colorectal tissue to elicit
chemopreventive activity. Interestingly, the levels of resveratrol and its
metabolites were consistently higher in tissues originating in the right
side of the colon as compared with the left. How this affects the progno-
sis of colorectal cancer remains to be investigated. The high variability of
the resveratrol metabolites in the tissue illustrates one of the key prob-
lems found in translating this drug to clinical trials.
In a pharmacokinetic study, Howells and colleagues have shown the
detection of higher levels of resveratrol in plasma (1942±1422 ng/mL)
and in hepatic tissue (1098± 1393 ng/g) following administration of
5 g of SRT501 in patients with colorectal cancer and hepatic metasta-
ses scheduled to undergo hepatectomy [50]. They found the micron-
ized resveratrol to be better tolerated by the patients, with all
adverse events being considered mild, compared to nonmicronized
resveratrol. Concentrations of resveratrol achieved in hepatic metas-
tases were able to elicit pharmacologic effect. A signiﬁcant increase
in cleaved caspase-3 immunoreactivity was observed in tumor tissue
when compared with equivalent tissue from subjects on placebo [50].
However, no signiﬁcant change was found in the other biomarkerstested, including AKT1, GSK-3, survivin, and PARP. Overall, SRT501 for-
mulated as a suspension seems to be better tolerated and have superior
bioavailability than nonmicronized resveratrol [19,42]. The authors
suggested that the doses would need to be moderately higher to
achieve signiﬁcant apoptosis induction.
Popat et al. conducted a trial to assess the safety, pharmacokinetics
and efﬁcacy of SRT501 alone or in combination with bortezomib, one
of the currently approved chemotherapy drugs for patients with multi-
ple myeloma. In this study, the researchers noticed several unexpected
adverse effects, including unexpected renal toxicity [44]. Additionally,
the trial was prematurely closed because of severe adverse events like
nausea, diarrhea, vomiting, fatigue, anemia, infections, andmost specif-
ically renal failure. As discussed by the authors, the observed renal fail-
ure in this trial seems to be speciﬁc to multiple myeloma patients only,
as renal impairment appears to be a common and serious complication
ofmyeloma that can occur in up to 50% patients. This trial highlights the
risks of developing resveratrol (and possibly other agents) in speciﬁc
disease populations, and suggests that it is necessary to consider the
association of secondary complications related with each disease
when designing resveratrol based clinical trials. In this case, it appears
that the existing increased risk of kidney problems inmultiplemyeloma
patients was further aggravated by the treatments. The reason for this
particular interaction at amolecular level is not known.However, deter-
mining the exact and detailedmechanism of action of resveratrol in this
cancer may be useful for future studies.
In another study, Zhu and colleagues have assessed the effects of res-
veratrol on methylation of certain breast cancer related proteins in
women who were at increased risk for breast cancer. To be included
in this study, womenmust have had i) a ﬁrst degree relativewith breast
cancer, ii) a Gail risk of N1.66% of developing breast cancer, iii) a breast
biopsy demonstrating atypical hyperplasia in situ, or iv) invasive breast
cancer (previously diagnosed but currently free of disease) [53]. The
effects of either 5 or 50 mg of trans-resveratrol twice per day (for 12
weeks) was studied on methylation of certain genes, as compared to
placebo. The study found decreased methylation of RASSF-1a with
increasing levels of trans-resveratrol and resveratrol-glucuronide in cir-
culation, andwith decreasing prostaglandin E2 (PGE2) expression in the
breast [53]. Increased levels of PGE2 as well as increased methylation of
RASSF-1a have been linkedwith disease progression from pre-cancer to
cancer in the breast [54,55]. Different parameters and longer follow-up
of this study may be relevant to decide whether short duration or con-
tinuous supplementation of resveratrol would be better for individuals
with increased breast cancer risk. This also underlines the importance
of determining relevant doses and treatment regimens for each type
of cancer or cancer-risk group.
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drop in circulating insulin-like growth factor (IGF)-I and IGF-binding
proteins (IGFBP)-3 in healthy volunteers [42]. This study suggested
that resveratrol may affect the IGF axis, possibly by direct effects on
IGF-I and/or IGFBP-3, and that these proteins may serve as potential
markers of chemopreventive efﬁcacy in human clinical trials against
cancer. Studies have suggested a relationship between the levels of
IGF-I and IGFBP-3 with risk of variety of human diseases including can-
cers [56]. These molecules critically inﬂuence many key aspects of can-
cer development, including apoptosis, cell differentiation, neoplastic
transformation and metastasis.
Overall, these completed trials are able to give us some key hints in
what needs to be considered when planning out new clinical trials, as
well as what ways to steer ongoing trials to make the most effective
treatment regimens.7.2. Ongoing and future clinical trials
The ongoing human clinical trials dealing with resveratrol against
cancer (according to ClinicalTrials.gov) are summarized in Table 2. It is
encouraging to see that researchers have learned lessons from previous
clinical trialswhile designing the new trials,whichwill hopefully lead to
better results. Out of the four ongoing trials, two are focused on colorec-
tal cancers. One of these studies (NCT00433576) is focused on deter-
mining the optimal dose of resveratrol that will result in bioactive
levels in the colon mucosa. This is important because even with all the
colon cancer research done with resveratrol, an optimal dose is yet to
be discovered. In addition, the researchers will explore the mechanistic
effects of resveratrol treatment of colorectal adenocarcinoma by deter-
mining if there are correlative levels of COX-2 and M1G
(pyrimido[1,2-a]purin-10(3H)-one) adduct in cancer tissues. This may
provide some useful information, as both of these molecules have
been shown to be modulated in colon cancer. The other colon cancer
trial that is under way (NCT00578396) is using seedless red grapes in
an attempt to determine the maximum dietary levels of resveratrol
that can be attained. This may be especially important for colon cancer
prevention, because new dietary recommendations could easily be
provided/devised for the human population.
The third study will determine the effects of resveratrol in neuro-
endocrine tumors (NCT01476592). This trial explores the tolerabili-
ty of 5 g resveratrol/day (in two doses) in patients with low grade
gastrointestinal tumors of neuroendocrine origin. This study will
also examine the level of Notch1 activation by resveratrol in these
patients, as Notch1 has been found to be a key molecule in this
type of cancer [57,58]. The last study (NCT00455416) is focused on
follicular lymphoma, and administers resveratrol as 100% grape
juice as a dietary intervention. The researchers will determine if this
mode of resveratrol administrationwill be able to inhibit cellular prolif-
eration and/ormodulate the inﬁltration of tumor cells in this malignan-
cy. This trial may provide useful information regarding a different and
possibly easier mode of resveratrol administration through dietary
means.
These trials should provide some useful information that may be
helpful in future detailed human studies aimed at bringing resveratrol
to the clinics for disease management. In addition, resveratrol con-
taining diets may be advocated for better health and disease preven-
tion. Although we seem to have learned from previous clinical trials,
there is always room for improvement. From the analysis of the stud-
ies described above, some areas to concentrate on are, i) a systems
biology approach to explore detailed global mechanisms, ii) working
out the ideal formulation(s), identifying novel combination(s) of res-
veratrol with other agents and drugs, and iii) personalized dosing
schedule. This will necessitate a step back and many more pilot studies
by researchers, but will likely result in much more fruitful outcome for
success in moving resveratrol from the bench to the bedside.8. Conclusion
Resveratrol has garnered intense attention from the public as well as
researchers. This interest stems from the fact that this small molecule
found in grapes and red wine has shown very promising results against
heart diseases, aging, metabolic disorders, and cancer in numerous
preclinical studies. This is perpetuated by the media and private corpo-
rations who want to be a part of this lucrative molecule. In fact, several
formulations of resveratrol are available as over-the-counter supple-
ments which claim beneﬁcial effects against various health conditions.
However, only limited efforts have been undertaken to translate the
preclinical success of this ‘wonder molecule’ to the clinics. There are
a number of challenges that need to be overcome in order to bring res-
veratrol from the bench to the bedside. The single biggest problem in
resveratrol's clinical translation appears to be its rapid metabolism
leading to a limited in vivo bioavailability. Pharmaceutical companies
and researchers are trying to combat this by either re-deriving or
reformulating resveratrol. Although the limited amount of clinical data
available so far is promising, intense and concerted efforts are required
from researchers, clinicians and the pharmaceutical industry to try to
overcome these obstacles.Acknowledgements
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